EasyM
Blood-based multiple myeloma MRD monitoring test using clonotypic peptide mass spectrometry to track M-protein.
- Developer
- Rapid Novor
- Intended use
- Mrd
- Cancer scope
- Multiple myeloma
- Specimen
- Whole blood-derived plasma/serum
- Molecular modality
- Protein
- Current version
- Current EasyM clinical configuration (2026-09)
- Evidence context
- 0 structured studies · 0 indexed performance results · 1 sources
Why can reported performance numbers differ? MDI keeps each result attached to its study, population, stage or stratum, test version and source rather than treating performance as a fixed property of the test.